PMGC Holdings Inc. (NASDAQ: ELAB) expanded its portfolio in fiscal 2025 through three acquisitions in the precision manufacturing and industrial packaging sectors, the company disclosed in its annual report filed March 30.
Management believes the acquisitions strengthen PMGC’s position in sectors where reliability and high switching costs support long-term customer retention and value creation.
The acquisitions included specialized packaging provider Pacific Sun Packaging, aerospace and defense manufacturer AGA Precision Systems, and a bolt-on asset acquisition of Indarg Engineering, Inc. to expand AGA’s machining capacity. The company noted that demand for certified, U.S.-based precision machine shops continues to grow, driven by defense spending and aerospace backlogs.
The strategy focuses on durable, high-value industries, positioning the company to capitalize on U.S. defense spending and the buildout of data center infrastructure.
The company's biopharmaceutical subsidiary, Northstrive Biosciences, also reported significant progress. Its lead asset, EL-22, an oral probiotic for preserving muscle mass in patients on GLP-1 weight loss treatments, received a clear path from the U.S. Food and Drug Administration to file for a Phase 2 clinical trial.
Northstrive also initiated a preclinical study for a second candidate, EL-32, and executed an exclusive license agreement with Modulant Biosciences LLC for animal health applications of its technology. An AI-driven drug discovery program with Yuva Biosciences, Inc. advanced to experimental validation, with results expected in the second quarter of 2026.
The acquisitions and pipeline progress signal PMGC's focus on long-term value in specialized, high-barrier-to-entry markets. Investors will watch for the Phase 2 initiation of EL-22 and further acquisitions in 2026 to gauge the strategy's execution.
This article is for informational purposes only and does not constitute investment advice.
